Foundation Medicine, Inc. (NASDAQ:FMI) tinted gains of +2.68% (+2.7 points) to US$103.4. The volume of 0.32 Million shares climbed down over an trading activity of 321.84 Million shares. EPS ratio determined by looking at last 12 month figures is -4.21. Over the same time span, the stock marked US$109.3 as its best level and the lowest price reached was US$31.7. The corporation has a market cap of US$4.05 Billion.
Foundation Medicine, Inc. (NASDAQ:FMI)’s earnings per share has been growing at a 15.5 percent rate over the past 5 year when average revenue increase was noted as 70.4 percent. The return on equity ratio or ROE stands at -299.6 percent while most common profitability ratio return on investment (ROI) was -175.5 percent. The company’s institutional ownership is monitored at 36.2 percent. The company’s net profit margin has achieved the current level of -85 percent and possesses 47.3 percent gross margin.
Daily Analyst Recommendations
A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 1 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 4 think it is Hold. Recently, analysts have updated the overall rating to 2.5. 1 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.
Intermolecular, Inc. (NASDAQ:IMI) is worth US$74.24 Million and has recently risen 2.67% to US$1.54. The latest exchange of 0.08 Million shares is below its average trading activity of 49.08 Million shares. The day began at US$1.5 but the price moved to US$1.45 at one point during the trading and finally capitulating to a session high of US$1.6. The stock tapped a 52-week high of US$1.65 while the mean 12-month price target for the shares is US$3.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.11, and a price to sales ratio of 2.01. For the past 5 years, the company’s revenue has grown -11.1%, while the company’s earnings per share has grown -64.2%. With an institutional ownership near 67.8%, it carries an earnings per share ratio of -0.11.
Inside Look At Analysts Reviews
Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 0 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 3.